Victoriano Garre- Department of Genetics and Microbiology, Faculty of Biology, University of Murcia, Murcia, Spain
Mucormycosis is an emerging infection caused by fungi of the order Mucorales that has recently gained public relevance due to the high incidence among COVID-19 patients in some countries. The reduced knowledge about Mucorales pathogenesis is due, in large part, to the historically low interest for these fungi fostered by their reluctance to be genetically manipulated. The recent introduction of more tractable genetic models together with an increasing number of available whole genome sequences and genomic analyses have improved our understanding of Mucorales biology and mucormycosis in the last ten years. This review summarizes the most significant advances in diagnosis, understanding of the innate and acquired resistance to antifungals, identification of new virulence factors and molecular mechanisms involved in the infection. The increased awareness about the disease and the recent successful genetic manipulation of previous intractable fungal models using CRISPR-Cas9 technology are expected to fuel the characterization of Mucorales pathogenesis, facilitating the development of effective treatments to fight this deadly infection.
Introduction
Mucormycosis is a deadly agioinvasive infection caused by fungi of the order Mucorales with an incidence that has grown in the last years (Prakash and Chakrabarti, 2019; Skiada et al., 2020), although this number is likely to be severely underestimated (Skiada et al., 2020; Soare et al., 2020). Traditionally, this infection has received scarce attention because of the low number of cases in comparison with other more frequent fungal infections, but the emerge of the SARS-CoV-2 disease (COVID-19) pandemic has increased the incidence of fungal infections, rising the concern about their risks (Ghosh et al., 2021). The upsurge in COVID-19-associated mucormycosis with a prevalence 50 times higher than the uppermost recorded data (Hussain et al., 2021) has highlighted the unmet need to better understand mucormycosis (Stone et al., 2021).
Mucormycosis is a complex fungal infection for several reasons. Despite affecting most frequently individuals with underlying pathologies reducing the immune response, around 19% are immunocompetent patients that have suffered trauma or burn wounds (Roden et al., 2005; Jeong et al., 2019b). In addition, the clinical presentation is diverse and linked to the underlying pathology with rhino-orbital-cerebral mucormycosis as the most frequent manifestation followed by cutaneous, pulmonary, disseminated, gastrointestinal, and others (Jeong et al., 2019b). Finally, it is caused by 38 different species corresponding to 11 genera, being Rhizopus the most frequent genus, followed by Mucor and Lichtheimia (Roden et al., 2005; Walther et al., 2019). Most knowledge about mucormycosis derived from these three genera, but fully understanding of the disease requires more work studying unusual Mucorales infections (Gomes et al., 2011).
The disease shows high mortality, and its reduction is confronted with several problems. The first one is the scarce tests available for the diagnosis in the early stages of the infection (Skiada et al., 2018; Skiada et al., 2020; Lackner et al., 2021). Thus, preemptive therapy for patients at a high risk for mucormycosis has been proposed as a strategy to reduce mortality (Chamilos et al., 2008). Once a diagnosis is made, management is challenging because treatment options are reduced, with surgery and amphotericin B therapy being the most extended and effective options. The actual problem is evidenced by the fact that mortality has not improved significantly in recent years despite the advent of newer antifungals (Skiada et al., 2018; Jeong et al., 2019a). The development of new efficient treatments faces the problem of poor knowledge about the Mucorales physiology, including molecular mechanisms that govern pathogenesis, which is motivated, in large part, by their genetic intractability (Soare et al., 2020). This review recapitulates the latest advances in the knowledge of Mucorales pathology aiming to highlight the major accomplishments needed to reduce the impact of mucormycosis on human health.
Development of Rapid and Specific Diagnosis Procedures Is an Urgent Need
Appropriate and timely treatment of Mucormycosis to reduce mortality rate requires early detection of the pathogen, which is one of the main targets of current research. Diagnosis is still being performed by classical methods comprising histology/microscopy and culture that show low sensitivity and need a long time, respectively (Skiada et al., 2018; Skiada et al., 2020; Lackner et al., 2021). Moreover, morphological identification is not reliable and molecular identification is strongly recommended (Sagatova et al., 2016). Despite internal transcribed spacer (ITS) sequencing is strongly supported, matrix assisted laser desorption ionization time of flight (MALDI-TOF) has been proved to be a reliable and rapid method for the identification at species level, although it relies on in-house databases (Schwarz et al., 2019). Consequently, an intense effort is being devoted to developing methods based on the detection of molecules that allow the rapid and specific identification of the pathogen. Many approaches have been successful in the identification of Mucorales by analyzing DNA from either tissue samples or circulating DNA, also called cell-free DNA (cfDNA), in blood and even urine using PCR-based methods (Millon et al., 2016; Baldin et al., 2018). High performance of Mucorales PCR in blood samples comes from the high cfDNA levels, which are probably caused by the fact that Mucorales are much more angioinvasive than other fungi (Millon et al., 2016). In addition, these methods are non-invasive and can provide earlier and rapid diagnosis, making them ideal. The main drawbacks are the lack of standardization and clinical evaluation. However, some initiatives are stimulating such as a multicenter study that showed good reproducibility and performance of quantitative PCR assays in serum samples, supporting the use of this technique as part of the diagnostic strategy for mucormycosis (Rocchi et al., 2021).
We should also follow up on the promising evolution of techniques with high sensitivity that analyze cfDNA in blood such as the already used whole genome sequencing (WGS) and forthcoming techniques based on CRISPR-Cas. WGS has been proved to be useful for molecular typing in outbreaks (Walther et al., 2020) and its application for early diagnosis using cfDNA in blood is promising (Shi et al., 2021). Several CRISPR-Cas-based point-of-care tests are in development or available to detect different viruses, which include a Cas nuclease coupled in most cases with detection by a lateral flow device (Ganbaatar and Liu, 2021). Despite they have not yet applied to fungal infections, their introduction could enhance the diagnosis of mucormycosis (Morio et al., 2020). There are additional incipient technical developments relying on the identify other molecules that all need further investigations. These comprise the use of serologic tests based on the recognition of fucomannan (Burnham-Marusich et al., 2018) and the analysis of breath volatile metabolites by thermal desorption gas chromatography/tandem mass spectrometry (Koshy et al., 2017).
Mucormycosis Is Not One Disease, but Many
Most fungal infections are defined by the genus of the causative species, but mucormycosis is caused by 38 different species corresponding to 11 genera (Walther et al., 2019), an intricate situation since some pathogenic mechanisms could be species-specific. Pursuing an ideal treatment to combat the disease would require studying the pathogenesis in more than one genus to find common molecular mechanisms to all pathogenic Mucorales. On top of that, intraspecific genetic variation is presumably very high in Mucorales, but few, if any, comprehensive analyses have been performed for its evaluation. The possibility of performing WGS affordably has provided some hints about this genetic variation. Thus, genome length of Rhizopus species is highly variable, especially within Rhizopus microsporus (Gryganskyi et al., 2018). In addition, sequencing of 72 isolates from patients and hospital and regional environments revealed a remarkable genetic diversity within species, even affecting the number of putative genes (Nguyen et al., 2020). This variability may have a profound effect on characteristics linked to pathogenesis and resistance to antifungals, explaining why different clinical isolates of a species show a wide range of resistance to different antifungals (Borman et al., 2017). Therefore, we urgently need pan-genomic analyses in Mucorales similar to that performed in Aspergillus fumigatus (Barber et al., 2021) to discover the intraspecific genetic variation associated with human infection. In fact, the A. fumigatus study points out that a single or a small number of reference genomes do not necessarily represent the species as a whole (Barber et al., 2021).
Mucorales Resistance to Antifungals
Mucorales show an intrinsic resistance to most antifungals used in clinic, except for amphotericin B, leaving clinicians with insufficient treatment options. This innate drug resistance could be linked to the widespread duplications of genome regions and whole genome in Mucorales (Ma et al., 2009), which also could affect pathogenesis. However, a few works have shed some light on the mechanisms that could explain this resistance. In one pivotal work, sequence alignment of the lanosterol 14α-demethylase CYP51 F5 proteins, the target for azoles, from several species revealed a conserved single amino acid substitution Y129F previously related to the resistance to short-tailed triazoles (Sagatova et al., 2016), suggesting that this change mediates the innate resistant of Mucorales to short-tailed triazoles (Caramalho et al., 2017).
Another common mechanism of acquired azole resistance involves the upregulation of multidrug transporters (Cowen et al., 2015; Revie et al., 2018). Deletion of two out of eight M. lusitanicus genes encoding putative ABC transporters of the pleiotropic drug resistance transporter subfamily only increased slightly the susceptibility to some azoles (Nagy et al., 2021). This small effect in antifungal sensibility could be in part explained by the upregulation of other transporter subfamily members, suggesting that the regulation of these genes are interconnected (Nagy et al., 2021).
In addition to the intrinsic resistance mechanisms described above, an epigenetic acquired mechanism has been described in M. lusitanicus that confers transient resistance. This mechanism generates RNA interference (RNAi)-dependent epimutants in response to the presence of a drug by silencing the gene encoding either the target protein (Calo et al., 2014) or the enzymes that convert the drug into a toxic compound (Chang et al., 2019). Interestingly, murine infection of Mucor led to increased rates of epimutation when isolates recovered from organs were exposed to the antifungal agent FK506, suggesting that growth in animal tissues could prime the rapid response of this mechanism to subsequent stresses, including antifungal exposure (Chang and Heitman, 2019). The ability of this epigenetic acquired resistance mechanism to target different genes suggests that it could contribute to the broad resistance of Mucorales to clinically available antifungal drugs (Chang et al., 2019). Despite these advances, additional work is required to understand the Mucorales mechanisms of antifungal resistance and their role in vivo infections due to the problems of correlating in vitro resistance with clinical outcome (Lamoth et al., 2021).
Host Invasion and Damage
Mucormycosis is initiated by asexual resting spores that get in contact with an epithelium that prevents invasion and hence, epithelial damage may result in mucormycosis. Interestingly, a genetically modified larval zebrafish model reproducing epithelial damage has been developed that can be instrumental to understand fungal attachment and invasion. This model has revealed that loss of epithelial integrity promotes fungal adhesion and invasion mediated by exposure of extracellular matrix components, while the epidermal growth factor (EGF) signaling pathway provide a protective effect (Wurster et al., 2021). In addition, an intense research has been carried out to identify both the spore coat and host proteins that interact to facilitate the entry of the fungus. All invasive Mucorales species analyzed contain genes coding for spore coat proteins CotH and their copy number correlates with clinical prevalence and the ability to cause invasive disease (Chibucos et al., 2016). At least in Rhizopus delemar, different CotH proteins interact with different host receptors depending on the tissue. CotH3 interacts with glucose-regulated protein 78 (GRP78) on nasal epithelial and endothelial cells, whereas CotH7 recognizes integrin β1 on alveolar epithelial cells, which activates EGF signalling to induce fungal invasion of host cells (Gebremariam et al., 2014; Watkins et al., 2018; Alqarihi et al., 2020). This combination of interactions could explain that patients with diabetic ketoacidosis ( DKA) are more susceptible to rhinoorbital/cerebral disease because they overexpress both CotH3 and GRP78 (Alqarihi et al., 2020).
Several works have suggested that Mucorales secrete proteins that could be toxic for the host cells. Aberrant vesicle trafficking in M. lusitanicus (Patiño-Medina et al., 2018; Patiño-Medina et al., 2019b) and tornadic shear stress in several Mucorales (Wurster et al., 2020) increase secretion of unknown proteins that result in higher virulence in animal models. However, the only toxin identified until now is mucoricin (Soliman et al., 2021), a protein secreted during the germination of R. delemar spores with structural and functional features similar to the plant toxin ricin that contributes to pathogenesis by enhancing angioinvasion, inflammation and tissue destruction. Importantly, the gene encoding for mucoricin is widely present in pathogenic Mucorales and hyphal extracts from some of them caused in vitro damage to human alveolar epithelial cells, suggesting that this toxin could be secreted by other Mucorales species (Soliman et al., 2021).
Understanding all the aspects of mucormycosis requires animal models that somehow simulate the comorbidities associated with the disease, although they rarely recapitulate clinical scenarios (Ben-Ami and Kontoyiannis, 2021). Despite the differences with humans, mouse is the preferred model to study infection because it is the best established laboratory mammal model with the same body temperature as humans (Jacobsen, 2019). Other vertebrates (rabbit and zebrafish) and alternative invertebrate hosts (Drosophila melanogaster, Galleria mellonella, and Caenorhabditis elegans), have been greatly contributed to characterize particular aspects of the disease. All models have advantages and disadvantages (Jacobsen, 2019) and the election depend on the answer to be addressed.
Understanding the Fungal Response to the Macrophage Attack
In addition to the physical barriers, the immune effector cells play a central role in halting the progression of the infection. Professional phagocytes, including macrophages and neutrophils, are rapidly recruited to the infection point, but spores are phagocytized predominantly by macrophages (Andrianaki et al., 2018). However, macrophage-mediated phagocytosis fails to kill the Mucorales spores with apparent species-specific results. In Rhizopus species, phagocytosis prevents spore germination, but they remain viable for, at least, 10 days post-infection of immunocompetent mice (Waldorf et al., 1984; Andrianaki et al., 2018). On the contrary, in Mucor species, macrophages of a murine cell line are unable to block in vitro germination that results in macrophage death by lysis (Li et al., 2011) and apoptosis (Lee et al., 2015), also observed in an adult zebrafish infection model (López-Muñoz et al., 2018). In addition, both genera induce phagosome maturation arrest mediated by cell wall melanin and the calcineurin signal pathway in Rhizopus (Andrianaki et al., 2018) and Mucor species (Lee et al., 2015; Vellanki et al., 2020), respectively. Resting spores of Lichtheimia corymbifera also inhibits the intracellular acidification of macrophages in vitro, independently from melanin (Hassan et al., 2021).
Despite the progress on Mucorales–macrophage interaction knowledge, more information is needed to understand the mechanisms used by Mucorales to survive inside the macrophage, which is supposed to facilitate dissemination. The advent of next generation sequencing and tractable genetic models, particularly M. lusitanicus, has informed about those regulatory mechanisms. Analysis of the interaction between R. delemar and macrophages in vitro revealed nutritional immunity via iron restriction inside the phagosome as an important host defense mechanism (Andrianaki et al., 2018) that provokes the induction of the majority of fungal genes implicated in iron acquisition and virulence (Ibrahim et al., 2010; Navarro-Mendoza et al., 2018). In addition, studying the response to phagocytosis in virulent and attenuated strains of M. lusitanicus discovered general and virulence-specific responses that probably are responsible for the metabolism shift to allow germination inside the phagosome and survival to macrophage attack, respectively (Pérez-Arques et al., 2019). Several genes were identified that play crucial role in germination inside the phagosome and virulence, including two encoding basic leucine zipper transcription factors (Atf1 and Atf2) that regulates germination at low pH, suggesting that an Atf-regulatory pathway is activated by the acidic environment of the phagosome (Pérez-Arques et al., 2019). Interestingly, most of the genes responding to phagocytosis, including atf1 and atf2, are repressed by a non-canonical RNAi pathway (NCRIP) during saprophytic growth, suggesting that interaction of spores with macrophages inhibits NCRIP leading to the activation of the genetic program to overcome host defense mechanisms (Pérez-Arques et al., 2020). The transduction pathways that regulate the NCRIP and other pathogenic processes are unknown, but the identification of heterotrimeric G proteins involved in M. lusitanicus virulence suggests that we may be approaching to their identification (Patiño-Medina et al., 2019a; Valle‐Maldonado et al., 2020).
New Genetic Tools to Study Gene Function
The last decade has produced a tremendous increase in the number of molecular techniques available to study the function of genes involved in pathogenesis. To date, Mucor is the Mucorales genus with the widest repertoire of genetic molecular tools to study gene function (Rodríguez-Frómeta et al., 2013; Binder et al., 2018; Nicolás et al., 2018; Vellanki et al., 2018; Navarro-Mendoza et al., 2019). Unfortunately, other relevant mucormycosis-causative genera lack comparable genetic toolbox and only the RNAi technology is available in Rhizopus (Ibrahim et al., 2010). Fortunately, this dismal situation is changing due to expansion of the CRISPR-Cas technology to medically relevant fungi (Morio et al., 2020). M. lusitanicus was again the first mucoralean species in which this technology was established and used for targeted mutation of several genes (Nagy et al., 2017). Similar approaches have been followed in R. delemar and L. corymbifera, but in these species, the procedures require optimization because they work exclusively in genes that produce a selectable phenotype after mutation (Bruni et al., 2019; Ibragimova et al., 2020), making unfeasible their widespread use. In this context, a promising plasmid-free CRISPR-Cas9-based procedure has been established for R. microsporus that produces stable transformants, allows targeted mutation of any gene, and uses microhomology repair templates, speeding up the whole process (Lax et al., 2021).
Future Directions
The continuous increase in the mucormycosis incidence, further spurred by COVID-19 pandemic, could have a bright side if the number of research groups working in the field and funding also rise. This upsurge in cases could favor the standardization and clinical evaluation of molecular methods for an early diagnosis of the disease and the development of new treatments. In addition, research in promising immunotherapies against fungal ligand (CotH proteins) and mucoricin that are effective in laboratory assays could have further progress to reach the clinic (Gebremariam et al., 2019; Soliman et al., 2021). The development of these therapies and others are a major unmet need because investigational antifungals under testing have limited activity against Mucorales (Lamoth et al., 2022). It is expected that coming years will bring advances in the understanding of the molecular mechanisms controlling pathogenesis by improving the tractability of mucormycosis models by the hand of the CRISPR-Cas technology. Special attention should be also dedicated to deciphering the mechanisms that confer intrinsic and acquired resistance to antifungals. It is worth noting that the current situation hinders the development of treatments to combat the disease because the advances derived from one species lack detailed validation in other species or genera. Therefore, it is urgent to produce the tools allowing result verification in several species to identify Achilles heel disease that helps in reducing mortality of mucormycosis.
Author Contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Funding
VG was funded by Fundación Séneca-Agencia de Ciencia y Tecnología de la Región de Murcia, Spain (20897/PI/18) and Agencia Estatal de Investigación (AEI), Spain (PGC2018-097452-B-I00, co-financed by FEDER).
Conflict of Interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Alqarihi, A., Gebremariam, T., Gu, Y., Swidergall, M., Alkhazraji, S., Soliman, S. S. M., et al. (2020). GRP78 and Integrins Play Different Roles in Host Cell Invasion During Mucormycosis. MBio 11, e01087–e01020. doi: 10.1128/mBio.01087-20
Andrianaki, A. M., Kyrmizi, I., Thanopoulou, K., Baldin, C., Drakos, E., Soliman, S. S. M., et al. (2018). Iron Restriction Inside Macrophages Regulates Pulmonary Host Defense Against Rhizopus Species. Nat. Commun. 9, 3333. doi: 10.1038/s41467-018-05820-2
Baldin, C., Soliman, S. S. M., Jeon, H. H., Alkhazraji, S., Gebremariam, T., Gu, Y., et al. (2018). PCR-Based Approach Targeting Mucorales-Specific Gene Gamily for Diagnosis of Mucormycosis. J. Clin. Microbiol. 56, e00746–e00718. doi: 10.1128/JCM.00746-18
Barber, A. E., Sae-Ong, T., Kang, K., Seelbinder, B., Li, J., Walther, G., et al. (2021). Aspergillus fumigatus Pan-Genome Analysis Identifies Genetic Variants Associated With Human Infection. Nat. Microbiol. 6, 1526–1536. doi: 10.1038/s41564-021-00993-x
Ben-Ami, R., Kontoyiannis, D. P. (2021). Resistance to Antifungal Drugs. Infect. Dis. Clin. North Am. 35, 279–311. doi: 10.1016/j.idc.2021.03.003
Binder, U., Navarro-Mendoza, M. I., Naschberger, V., Bauer, I., Nicolas, F. E., Pallua, J. D., et al. (2018). Generation of a Mucor circinelloides Reporter Strain—A Promising New Tool to Study Antifungal Drug Efficacy and Mucormycosis. Genes (Basel) 9, 613. doi: 10.3390/genes9120613
Borman, A., Fraser, M., Palmer, M., Szekely, A., Houldsworth, M., Patterson, Z., et al. (2017). MIC Distributions and Evaluation of Fungicidal Activity for Amphotericin B, Atraconazole, Voriconazole, Posaconazole and Saspofungin and 20 Species of Pathogenic Filamentous Fungi Determined Using the CLSI Broth Microdilution Method. J. Fungi 3, 27. doi: 10.3390/jof3020027
Bruni, G. O., Zhong, K., Lee, S. C., Wang, P. (2019). CRISPR-Cas9 Induces Point Mutation in the Mucormycosis Fungus Rhizopus delemar. Fungal Genet. Biol. 124, 1–7. doi: 10.1016/j.fgb.2018.12.002
Burnham-Marusich, A. R., Hubbard, B., Kvam, A. J., Gates-Hollingsworth, M., Green, H. R., Soukup, E., et al. (2018). Conservation of Mannan Synthesis in Fungi of the Zygomycota and Ascomycota Reveals a Broad Diagnostic Target. mSphere 3, e00094–e00018. doi: 10.1128/mSphere.00094-18
Calo, S., Shertz-Wall, C., Lee, S. C., Bastidas, R. J., Nicolás, F. E., Granek, J. A., et al. (2014). Antifungal Drug Resistance Evoked via RNAi-Dependent Epimutations. Nature 513, 555–558. doi: 10.1038/nature13575
Caramalho, R., Tyndall, J. D. A., Monk, B. C., Larentis, T., Lass-Flörl, C., Lackner, M. (2017). Intrinsic Short-Tailed Azole Resistance in Mucormycetes is Due to an Evolutionary Conserved Aminoacid Substitution of the Lanosterol 14α-Demethylase. Sci. Rep. 7, 15898. doi: 10.1038/s41598-017-16123-9
Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2008). Delaying Amphotericin B-Based Frontline Therapy Significantly Increases Mortality Among Patients With Hematologic Malignancy Who Have Zygomycosis. Clin. Infect. Dis. 47, 503–509. doi: 10.1086/590004
Chang, Z., Billmyre, R. B., Lee, S. C., Heitman, J. (2019). Broad Antifungal Resistance Mediated by RNAi-Dependent Epimutation in the Basal Human Fungal Pathogen Mucor circinelloides. PloS Genet. 15, e1007957. doi: 10.1371/journal.pgen.1007957
Chang, Z., Heitman, J. (2019). Drug-Resistant Epimutants Exhibit Organ-Specific Stability and Induction During Murine Infections Caused by the Human Fungal Pathogen Mucor circinelloides. MBio 10, e02579–e02519. doi: 10.1128/mBio.02579-19
Chau, A. S., Chen, G., McNicholas, P. M., Mann, P. A. (2006). Molecular Basis for Enhanced Activity of Posaconazole Against Absidia corymbifera and Rhizopus oryzae. Antimicrob. Agents Chemother. 50, 3917–3919. doi: 10.1128/AAC.00747-06
Chibucos, M. C., Soliman, S., Gebremariam, T., Lee, H., Daugherty, S., Orvis, J., et al. (2016). An Integrated Genomic and Transcriptomic Survey of Mucormycosis-Causing Fungi. Nat. Commun. 7, 12218. doi: 10.1038/ncomms12218
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., et al. (2019). Global Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation With the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 19, e405–e421. doi: 10.1016/S1473-3099(19)30312-3
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., Perlin, D. S. (2015). Mechanisms of Antifungal Drug Resistance. Cold Spring Harb. Perspect. Med. 5, a019752. doi: 10.1101/cshperspect.a019752
Ganbaatar, U., Liu, C. (2021). CRISPR-Based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics. Front. Cell. Infect. Microbiol. 11, 373. doi: 10.3389/FCIMB.2021.663949/BIBTEX
Gebremariam, T., Alkhazraji, S., Soliman, S. S. M., Gu, Y., Jeon, H. H., Zhang, L., et al. (2019). Anti-CotH3 Antibodies Protect Mice From Mucormycosis by Prevention of Invasion and Augmenting Opsonophagocytosis. Sci. Adv. 5, eaaw1327. doi: 10.1126/sciadv.aaw1327
Gebremariam, T., Liu, M., Luo, G., Bruno, V., Phan, Q. T., Waring, A. J., et al. (2014). CotH3 Mediates Fungal Invasion of Host Cells During Mucormycosis. J. Clin. Invest. 124, 237–250. doi: 10.1172/JCI71349
Ghosh, A., Sarkar, A., Paul, P., Patel, P. (2021). The Rise in Cases of Mucormycosis, Candidiasis and Aspergillosis Amidst COVID19. Fungal Biol. Rev. 38, 67–91. doi: 10.1016/j.fbr.2021.09.003
Gomes, M. Z. R., Lewis, R. E., Kontoyiannis, D. P. (2011). Mucormycosis Caused by Unusual Mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia Species. Clin. Microbiol. Rev. 24, 411–445. doi: 10.1128/CMR.00056-10
Gryganskyi, A. P., Golan, J., Dolatabadi, S., Mondo, S., Robb, S., Idnurm, A., et al. (2018). Phylogenetic and Phylogenomic Definition of Rhizopus Species. G3 8, 2007–2018. doi: 10.1534/g3.118.200235
Hassan, M. I. A., Keller, M., Hillger, M., Binder, U., Reuter, S., Herold, K., et al. (2021). The Impact of Episporic Modification of Lichtheimia corymbifera on Virulence and Interaction With Phagocytes. Comput. Struct. Biotechnol. J. 19, 880–896. doi: 10.1016/j.csbj.2021.01.023
Hussain, S., Riad, A., Singh, A., Klugarová, J., Antony, B., Banna, H., et al. (2021). Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. J. Fungi 7, 985. doi: 10.3390/JOF7110985/S1
Ibragimova, S., Szebenyi, C., Sinka, R., Alzyoud, E. I., Homa, M., Vágvölgyi, C., et al. (2020). CRISPR-Cas9-Based Mutagenesis of the Mucormycosis-Causing Fungus Lichtheimia corymbifera. Int. J. Mol. Sci. 21, 1–11. doi: 10.3390/ijms21103727
Ibrahim, A. S., Gebremariam, T., Lin, L., Luo, G., Husseiny, M. I., Skory, C. D., et al. (2010). The High Affinity Iron Permease is a Key Virulence Factor Required for Rhizopus oryzae Pathogenesis. Mol. Microbiol. 77, 587–604. doi: 10.1111/j.1365-2958.2010.07234.x
Jacobsen, I. D. (2019). Animal Models to Study Mucormycosis. J. Fungi 5, 27. doi: 10.3390/jof5020027
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Chen, S. C. A., et al. (2019a). Contemporary Management and Clinical Outcomes of Mucormycosis: A Systematic Review and Meta-Analysis of Case Reports. Int. J. Antimicrob. Agents 53, 589–597. doi: 10.1016/j.ijantimicag.2019.01.002
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., et al. (2019b). The Epidemiology and Clinical Manifestations of Mucormycosis: A Systematic Review and Meta-Analysis of Case Reports. Clin. Microbiol. Infect. 25, 26–34. doi: 10.1016/J.CMI.2018.07.011
Koshy, S., Ismail, N., Astudillo, C. L., Haeger, C. M., Aloum, O., Acharige, M. T., et al. (2017). Breath-Based Diagnosis of Invasive Mucormycosis (Im). Open Forum Infect. Dis. 4, S53–S54. doi: 10.1093/OFID/OFX162.124
Lackner, N., Posch, W., Lass-Flörl, C. (2021). Microbiological and Molecular Diagnosis of Mucormycosis: From Old to New. Microorganisms 9, 1518. doi: 10.3390/microorganisms9071518
Lamoth, F., Lewis, R. E., Kontoyiannis, D. P. (2021). Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. J. Fungi 7, 17. doi: 10.3390/jof7010017
Lamoth, F., Lewis, R. E., Kontoyiannis, D. P. (2022). Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. Clin. Infect. Dis. 5, 27. doi: 10.1093/cid/ciab1070
Lax, C., Navarro-Mendoza, M. I., Pérez-Arques, C., Navarro, E., Nicolás, F. E., Garre, V. (2021). Stable and Reproducible Homologous Recombination Enables CRISPR-Based Engineering in the Fungus Rhizopus microsporus. Cell Rep. Methods 1, 100124. doi: 10.1016/j.crmeth.2021.100124
Lee, S. C., Li, A., Calo, S., Inoue, M., Tonthat, N. K., Bain, J. M., et al. (2015). Calcineurin Orchestrates Dimorphic Transitions, Antifungal Drug Responses and Host-Pathogen Interactions of the Pathogenic Mucoralean Fungus Mucor circinelloides. Mol. Microbiol. 97, 844–865. doi: 10.1111/mmi.13071
Li, C. H., Cervantes, M., Springer, D. J., Boekhout, T., Ruiz-Vazquez, R. M., Torres-Martinez, S. R., et al. (2011). Sporangiospore Size Dimorphism is Linked to Virulence of Mucor circinelloides. PloS Pathog. 7, e1002086. doi: 10.1371/journal.ppat.1002086
López-Muñoz, A., Nicolás, F. E., García-Moreno, D., Pérez-Oliva, A. B., Navarro-Mendoza, M. I., Hernández-Oñate, M. A., et al. (2018). An Adult Zebrafish Model Reveals That Mucormycosis Induces Apoptosis of Infected Macrophages. Sci. Rep. 8, 12802. doi: 10.1038/s41598-018-30754-6
Ma, L. J., Ibrahim, A. S., Skory, C., Grabherr, M. G., Burger, G., Butler, M., et al. (2009). Genomic Analysis of the Basal Lineage Fungus Rhizopus oryzae Reveals a Whole-Genome Duplication. PloS Genet. 5, e1000549. doi: 10.1371/journal.pgen.1000549
Millon, L., Herbrecht, R., Grenouillet, F., Morio, F., Alanio, A., Letscher-Bru, V., et al. (2016). Early Diagnosis and Monitoring of Mucormycosis by Detection of Circulating DNA in Serum: Retrospective Analysis of 44 Cases Collected Through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin. Microbiol. Infect. 22, 810.e1–810.e8. doi: 10.1016/j.cmi.2015.12.006
Morio, F., Lombardi, L., Butler, G. (2020). The CRISPR Toolbox in Medical Mycology: State of the Art and Perspectives. PloS Pathog. 16, e1008201. doi: 10.1371/journal.ppat.1008201
Nagy, G., Kiss, S., Varghese, R., Bauer, K., Szebenyi, C., Kocsubé, S., et al. (2021). Characterization of Three Pleiotropic Drug Resistance Transporter Genes and Their Participation in the Azole Resistance of Mucor circinelloides. Front. Cell. Infect. Microbiol. 11, 660347. doi: 10.3389/fcimb.2021.660347
Nagy, G., Szebenyi, C., Csernetics, Á., Vaz, A. G., Tóth, E. J., Vágvölgyi, C., et al. (2017). Development of a Plasmid Free CRISPR-Cas9 System for the Genetic Modification of Mucor circinelloides. Sci. Rep. 7, 16800. doi: 10.1038/s41598-017-17118-2
Navarro-Mendoza, M. I., Pérez-Arques, C., Murcia, L., Martínez-García, P., Lax, C., Sanchis, M., et al. (2018). Components of a New Gene Family of Ferroxidases Involved in Virulence are Functionally Specialized in Fungal Dimorphism. Sci. Rep. 8, 7660. doi: 10.1038/s41598-018-26051-x
Navarro-Mendoza, M. I., Pérez-Arques, C., Panchal, S., Nicolás, F. E., Mondo, S. J., Ganguly, P., et al. (2019). Early Diverging Fungus Mucor circinelloides Lacks Centromeric Histone CENP-A and Displays a Mosaic of Point and Regional Centromeres. Curr. Biol. 29, 3791–3802.e6. doi: 10.1016/j.cub.2019.09.024
Nguyen, M. H., Kaul, D., Muto, C., Cheng, S. J., Richter, R. A., Bruno, V. M., et al. (2020). Genetic Diversity of Clinical and Environmental Mucorales Isolates Obtained From an Investigation of Mucormycosis Cases Among Solid Organ Transplant Recipients. Microb. Genomics 6, e000473. doi: 10.1099/MGEN.0.000473
Nicolás, F. E., Navarro-Mendoza, M. I., Pérez-Arques, C., López-García, S., Navarro, E., Torres-Martínez, S., et al. (2018). “Molecular Tools for Carotenogenesis Analysis in the Mucoral Mucor circinelloides,” in Methods in Molecular Biology (New York, NY: Humana Press), 221–237. doi: 10.1007/978-1-4939-8742-9_13
Patiño-Medina, J. A., Maldonado-Herrera, G., Pérez-Arques, C., Alejandre-Castañeda, V., Reyes-Mares, N. Y., Valle-Maldonado, M. I., et al. (2018). Control of Morphology and Virulence by ADP-Ribosylation Factors (Arf) in Mucor circinelloides. Curr. Genet. 64, 853–869. doi: 10.1007/s00294-017-0798-0
Patiño-Medina, J. A., Reyes-Mares, N. Y., Valle-Maldonado, M. I., Jácome-Galarza, I. E., Pérez-Arques, C., Nuñez-Anita, R. E., et al. (2019a). Heterotrimeric G-Alpha Subunits Gpa11 and Gpa12 Define a Transduction Pathway That Control Spore Size and Virulence in Mucor circinelloides. PloS One 14, e0226682. doi: 10.1371/journal.pone.0226682
Patiño-Medina, J. A., Valle-Maldonado, M. I., Maldonado-Herrera, G., Pérez-Arques, C., Jácome-Galarza, I. E., Díaz-Pérez, C., et al. (2019b). Role of Arf-Like Proteins (Arl1 and Arl2) of Mucor circinelloides in Virulence and Antifungal Susceptibility. Fungal Genet. Biol. 129, 40–51. doi: 10.1016/j.fgb.2019.04.011
Pérez-Arques, C., Navarro-Mendoza, M. I., Murcia, L., Lax, C., Martínez-García, P., Heitman, J., et al. (2019). Mucor circinelloides Thrives Inside the Phagosome Through an Atf-Mediated Germination Pathway. MBio 10, e02765–e02718. doi: 10.1128/mBio.02765-18
Pérez-Arques, C., Navarro-Mendoza, M. I., Murcia, L., Navarro, E., Garre, V., Nicolás, F. E. (2020). A non-Canonical RNAi Pathway Controls Virulence and Genome Stability in Mucorales. PloS Genet. 16, e1008611. doi: 10.1371/journal.pgen.1008611
Prakash, H., Chakrabarti, A. (2019). Global Epidemiology of Mucormycosis. J. Fungi 5, E26. doi: 10.3390/jof5010026
Revie, N. M., Iyer, K. R., Robbins, N., Cowen, L. E. (2018). Antifungal Drug Resistance: Evolution, Mechanisms and Impact. Curr. Opin. Microbiol. 45, 70–76. doi: 10.1016/j.mib.2018.02.005
Rocchi, S., Scherer, E., Mengoli, C., Alanio, A., Botterel, F., Bougnoux, M. E., et al. (2021). Interlaboratory Evaluation of Mucorales PCR Assays for Testing Serum Specimens: A Study by the Fungal PCR Initiative and the Modimucor Study Group. Med. Mycol. 59, 126–138. doi: 10.1093/mmy/myaa036
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., et al. (2005). Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clin. Infect. Dis. 41, 634–653. doi: 10.1086/432579
Rodríguez-Frómeta, R. A., Gutiérrez, A., Torres-Martínez, S., Garre, V. (2013). Malic Enzyme Activity is Not the Only Bottleneck for Lipid Accumulation in the Oleaginous Fungus Mucor circinelloides. Appl. Microbiol. Biotechnol. 97, 3063–3072. doi: 10.1007/s00253-012-4432-2
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Sabherwal, M., Tyndall, J. D. A., Monk, B. C. (2016). Triazole Resistance Mediated by Mutations of a Conserved Active Site Yyrosine in Fungal lanosterol 14α-Demethylase. Sci. Rep 6, 26213. doi: 10.1038/srep26213
Schwarz, P., Guedouar, H., Laouiti, F., Grenouillet, F., Dannaoui, E. (2019). Identification of Mucorales by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. J. Fungi 5, 56. doi: 10.3390/JOF5030056
Shi, L., Zhao, X., Yan, X., Liu, Y., Liu, Y., Cao, H., et al. (2021). Aggressive Disseminated Rhizomucor pusillus Infection in a Ph-Like Acute Lymphoblastic Leukemia Patient: Early Detection by Cell-Free DNA Next-Generation Sequencing. J. Infect. Chemother. 28, 459–464. doi: 10.1016/j.jiac.2021.12.007
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., Petrikkos, G. (2018). Challenges in the Diagnosis and Treatment of Mucormycosis. Med. Mycol. 56, S93–S101. doi: 10.1093/mmy/myx101
Skiada, A., Pavleas, I., Drogari-Apiranthitou, M. (2020). Epidemiology and Diagnosis of Mucormycosis: An Update. J. Fungi 6, 265. doi: 10.3390/jof6040265
Soare, A. Y., Watkins, T. N., Bruno, V. M. (2020). Understanding Mucormycoses in the Age of “Omics.” Front. Genet. 11, 699. doi: 10.3389/fgene.2020.00699
Soliman, S. S. M., Baldin, C., Gu, Y., Singh, S., Gebremariam, T., Swidergall, M., et al. (2021). Mucoricin is a Ricin-Like Toxin That is Critical for the Pathogenesis of Mucormycosis. Nat. Microbiol. 6, 313–326. doi: 10.1038/s41564-020-00837-0
Stone, N., Gupta, N., Schwartz, I. (2021). Mucormycosis: Time to Address This Deadly Fungal Infection. Lancet Microbe 2, e343–e344. doi: 10.1016/S2666-5247(21)00148-8
Valle-Maldonado, M. I., Patiño-Medina, J. A., Pérez-Arques, C., Reyes-Mares, N. Y., Jácome-Galarza, I. E., Ortíz-Alvarado, R., et al. (2020). The Heterotrimeric G-Protein Beta Subunit Gpb1 Controls Hyphal Growth Under Low Oxygen Conditions Through the Protein Kinase A Pathway and is Essential for Virulence in the Fungus Mucor circinelloides. Cell. Microbiol. 22, e13236. doi: 10.1111/cmi.13236
Vellanki, S., Billmyre, R. B., Lorenzen, A., Campbell, M., Turner, B., Huh, E. Y., et al. (2020). A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides. MBio 11, e02949-19. doi: 10.1128/mBio.02949-19
Vellanki, S., Navarro-Mendoza, M. I., Garcia, A. B., Murcia, L., Perez-Arques, C., Garre, V., et al. (2018). Mucor circinelloides: Growth, Maintenance and Genetic Manipulation. Curr. Protoc. Microbiol. 49, e53. doi: 10.1002/jbmr.548.Cell
Waldorf, A. R., Levitz, S. M., Diamond, R. D. (1984). In Vivo Bronchoalveolar Macrophage Defense Against Rhizopus oryzae and Aspergillus fumigatus. J. Infect. Dis. 150, 752–760. doi: 10.1093/infdis/150.5.752
Walther, G., Wagner, L., Kurzai, O. (2019). Updates on the Taxonomy of Mucorales With an Emphasis on Clinically Important Taxa. J. Fungi 5, 106. doi: 10.3390/jof5040106
Walther, G., Wagner, L., Kurzai, O. (2020). Outbreaks of Mucorales and the Species Involved. Mycopathologia 185, 765–781. doi: 10.1007/s11046-019-00403-1
Watkins, T. N., Gebremariam, T., Swidergall, M., Shetty, A. C., Graf, K. T., Alqarihi, A., et al. (2018). Inhibition of EGFR Signaling Protects From Mucormycosis. MBio 9, e01384-18. doi: 10.1128/mBio.01384-18
Wurster, S., Ruiz, O. E., Samms, K. M., Tatara, A. M., Albert, N. D., Kahan, P. H., et al. (2021). EGF-Mediated Suppression of Cell Extrusion During Mucosal Damage Attenuates Opportunistic Fungal Invasion. Cell Rep. 34, 108896. doi: 10.1016/j.celrep.2021.108896
Keywords: CRISPR-Cas, diagnosis, antifungal resistance, phagocytosis, infection, macrophages
Citation: Garre V (2022) Recent Advances and Future Directions in the Understanding of Mucormycosis. Front. Cell. Infect. Microbiol. 12:850581. doi: 10.3389/fcimb.2022.850581
Received: 07 January 2022; Accepted: 04 February 2022;
Published: 24 February 2022.
Edited by:
Robert T. Wheeler, University of Maine, United StatesReviewed by:
Dimitrios P. Kontoyiannis, University of Texas MD Anderson Cancer Center, United StatesCopyright © 2022 Garre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Victoriano Garre, vgarre@um.es